Qiagen N.V.

NYSE:QGEN

Medical - Diagnostics & Research

Healthcare
$49.56 -0.96%

-$0.35 today

Market cap
$10.23B
Beta
0.66
P/E (TTM)
18.6
EPS (TTM)
$1.94
Dividend yield
0.69%
52W Low $32.53High $57.82

Volume 4.26M

Average 2.07M

QGEN Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Qiagen N.V.NYSE: QGEN

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation outflow shrinks to $0

Q2 FY2026 stock-based compensation was $0, compared with $10.76M a year earlier. Trailing-twelve-month stock-based compensation was $36.96M. Over 3 fiscal years it compounded at +0.6% a year.

Context

  • Stock-based compensation amounted to 2.4% of revenue in FY2025, up 0.2 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of $9.24M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$50.4M+15.5% YoY
LTMJun 2026
$36.96M-13.6% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year+15.5%——
3-year CAGR+0.6%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
50.4M USD
Year-over-year change
+15.5%
4-year CAGR
+7.0%

Stock-Based Compensation vs competitors

How QGEN compares with its peers on the latest reported figures

  • QGEN's LTM Jun 2026 stock-based compensation of $36.96M is the 7th largest of the 11 companies compared; the peer median is $44.45M.
  • Its year-over-year change of -13.6% is the 5th highest of 10, against a peer median of -20.9%.
  • Stock-based compensation amounts to 1.8% of revenue for QGEN, versus a peer median of 1.8%.
QGEN Competitors Peer median
Stock-Based Compensation for QGEN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DHRDanaher CorporationLTM Sep 2026$297M +1.7%+0.3%1.2%
AAgilent Technologies, Inc.LTM Jul 2026$131M +2.3%+0.8%1.8%
TXG10x Genomics, Inc.LTM Jun 2026$98.74M -20.9%-7.3%16.0%
TMOThermo Fisher Scientific Inc.LTM Sep 2026$84M —+0.3%0.2%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$45.8M +43.1%-1.6%1.8%
TECHBio-Techne CorporationLTM Sep 2026$43.09M +56.0%+1.8%3.5%
QGENQiagen N.V.LTM Jun 2026$36.96M -13.6%+0.6%1.8%
RGENRepligen CorporationLTM Jun 2026$33.29M -26.1%+6.1%4.2%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026$26M -36.2%—12.5%
RVTYRevvity, Inc.LTM Jul 2026$24.43M -27.0%-23.7%0.8%
BRKRBruker CorporationLTM Jun 2026$0 -100.0%-10.0%0.0%
Peer median (excluding QGEN) $44.45M-20.9%+0.3%1.8%

Competitors are the stored peer set for QGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income512.6M423.21M341.3M83.59M424.88M
Depreciation & Amortization214.93M208.4M205.34M203.27M193.75M
Deferred Income Tax(5.29M)(9.6M)10.73M(23.04M)(20.07M)
Stock-Based Compensation38.39M49.51M47.1M43.63M50.4M
Change in Working Capital(130.01M)(31.88M)(186.96M)135.45M(34.51M)
Accounts Receivables(7.4M)15.45M(55.12M)12.22M(36.39M)
Inventory(81.8M)(61.95M)(44.79M)87.76M(848K)
Accounts Payables(5.98M)(1.76M)(22.42M)1.45M(8.42M)
Other Working Capital(34.83M)16.37M(64.64M)34.03M11.15M
Other Non-Cash Items8.38M75.63M41.94M230.65M39.88M
Operating Cash Flow639M715.26M459.46M673.55M654.33M
Capital Expenditures(206.53M)(149.34M)(162.8M)(167.17M)(201.05M)
Acquisitions (Net)(16.63M)(63.65M)(149.53M)0(291.23M)
Purchases of Investments(400.3M)(1.39B)(979.32M)(688.38M)(371.82M)
Sales of Investments359.56M883.08M1.27B584.98M597.06M
Other Investing Activities61.47M(9.77M)(66.55M)21.35M(32.16M)
Investing Cash Flow(202.43M)(726.76M)(87.66M)(249.23M)(305.28M)
Debt Repayment(41.35M)(108.55M)(436.76M)(107.33M)208.15M
Common Stock Issued7.92M0000
Common Stock Repurchased(99.99M)(25.36M)(17.68M)(292.1M)(307.36M)
Dividends Paid0000(54.24M)
Other Financing Activities(16.95M)8.11M20.61M(23.47M)(25.53M)
Financing Cash Flow(150.37M)(125.8M)(433.83M)(422.9M)(178.98M)
Effect of Forex Changes(3.68M)(12.55M)(558K)(5.96M)5.38M
Net Change in Cash282.53M(149.85M)(62.59M)(4.53M)175.45M
Free Cash Flow432.47M565.93M296.65M506.38M453.28M

Qiagen N.V.

NYSE:QGEN

Intrinsic Alpha fair value

Locked

Current Price

$49.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.